Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.65 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 4/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
| ▸ | CASP7 | P55210 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8350565 | 0.79 | KDM4E (0.71) | KDM4EALDH1A1MAPK14LMNANPC1 | |
| SCHEMBL21577712 | 0.77 | KDM4E (0.53) | KDM4EALDH1A1LMNANPC1RAB9A | |
| SCHEMBL24862850 | 0.76 | KDM4E (0.67) | KDM4EALDH1A1LMNANPC1RAB9A | |
| SCHEMBL14759162 | 0.76 | KDM4E (0.71) | KDM4EALDH1A1LMNANPC1RAB9A | |
| SCHEMBL5373208 | 0.76 | KDM4E (0.71) | KDM4EALDH1A1LMNANPC1RAB9A | |
| SCHEMBL5359262 | 0.76 | KDM4E (0.71) | KDM4EALDH1A1LMNANPC1RAB9A | |
| SCHEMBL12797503 | 0.75 | KDM4E (0.70) | KDM4EALDH1A1LMNANPC1RAB9A | |
| Hydrochloric Acid SCHEMBL14759243 | 0.74 | KDM4E (0.69) | KDM4EALDH1A1LMNANPC1RAB9A | |
| SCHEMBL18359398 | 0.74 | PDE2A (0.44) | KDM4EALDH1A1MAPK14MAPK1DNMT1 | |
| SCHEMBL24273206 | 0.73 | KDM4E (0.67) | KDM4EALDH1A1LMNANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4252755-A2 | THERAPEUTIC COMPOUNDS | C4x Discovery Limited (GB) | 2023-10-04 | — | — | EP | disclosed |
| US-20230159511-A1 | TETRAHYDROISOQUINOLINE COMPOUNDS AS NRF2 ACTIVATORS | C4X DISCOVERY LIMITED (GB) | 2023-05-25 | — | — | US | disclosed |
| WO-2023073364-A1 | TETRAHYDROISOQUINOLINE COMPOUNDS THAT ARE KEAP1 BINDERS | C4X DISCOVERY LIMITED (GB) | 2023-05-04 | — | — | WO | disclosed |
| US-20220002286-A1 | THERAPEUTIC COMPOUNDS | C4X DISCOVERY LIMITED (GB) | 2022-01-06 | — | — | US | disclosed |
| WO-2021214472-A1 | TETRAHYDROISOQUINOLINE COMPOUNDS AS NRF2 ACTIVATORS | C4X DISCOVERY LIMITED (GB) | 2021-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159511-A1 | TETRAHYDROISOQUINOLINE COMPOUNDS AS NRF2 ACTIVATORS | NFE2L2, KEAP1, NQO1 | KDM4E 2935/4885ALDH1A1 773/4885MAPK14 1353/4885 |
| US-20220002286-A1 | THERAPEUTIC COMPOUNDS | NFE2L2, KEAP1, NQO1 | KDM4E 3963/4885ALDH1A1 307/4885MAPK14 2113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.